Introduction: Type 2 diabetes mellitus (T2DM) patients have a variable response profile to the P2Y12receptor antagonist clopidogrel. P2Y12receptor signalling promotes platelet procoagulant activity. The aim of this study was to determine if T2DM patients with suboptimal clopidogrel response have greater platelet procoagulant activity compared with optimal responders and evaluate if this can be modulated by enhancing P2Y12receptor inhibition. Materials and Methods: A total of 50 T2DM patients in a steady state phase of clopidogrel therapy were studied. Suboptimal responders were randomly assigned to standard (75 mg) or high (150 mg) clopidogrel maintenance therapy for one-month. Afterwards, all patients resumed standard therapy. Platelet procoagulant activity assessed by thrombin-induced platelet-fibrin clot formation using thrombelastography (TEG) was determined at baseline, one-month post-randomization, and one-month after resuming standard therapy. Results: In the overall study population, the reaction time (R), a measure of time to initial thrombin induced platelet-fibrin clot formation, and the time to maximum rate of thrombin generation (TMRTG) values were 6.3 ± 1.7 and 7.6 ± 1.9 minutes, respectively. Suboptimal clopidogrel responders (n = 30) had acceleration of R (p = 0.002) and TMRTG (p = 0.002) compared to optimal responders (n = 20). Suboptimal clopidogrel responders treated with a 150 mg dose showed prolongation of R (p = 0.0001) and TMRTG (p < 0.0001), which returned to baseline values after resuming standard dosage. No differences were observed among patients randomized to 75 mg. Conclusions: T2DM patients with suboptimal clopidogrel response have enhanced platelet procoagulant activity compared to patients with optimal response, which can be down-regulated by more potent platelet P2Y12inhibition using high clopidogrel maintenance dosing. © 2008 Elsevier Ltd. All rights reserved.

Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients

Capranzano, Piera
Writing – Review & Editing
;
2009

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) patients have a variable response profile to the P2Y12receptor antagonist clopidogrel. P2Y12receptor signalling promotes platelet procoagulant activity. The aim of this study was to determine if T2DM patients with suboptimal clopidogrel response have greater platelet procoagulant activity compared with optimal responders and evaluate if this can be modulated by enhancing P2Y12receptor inhibition. Materials and Methods: A total of 50 T2DM patients in a steady state phase of clopidogrel therapy were studied. Suboptimal responders were randomly assigned to standard (75 mg) or high (150 mg) clopidogrel maintenance therapy for one-month. Afterwards, all patients resumed standard therapy. Platelet procoagulant activity assessed by thrombin-induced platelet-fibrin clot formation using thrombelastography (TEG) was determined at baseline, one-month post-randomization, and one-month after resuming standard therapy. Results: In the overall study population, the reaction time (R), a measure of time to initial thrombin induced platelet-fibrin clot formation, and the time to maximum rate of thrombin generation (TMRTG) values were 6.3 ± 1.7 and 7.6 ± 1.9 minutes, respectively. Suboptimal clopidogrel responders (n = 30) had acceleration of R (p = 0.002) and TMRTG (p = 0.002) compared to optimal responders (n = 20). Suboptimal clopidogrel responders treated with a 150 mg dose showed prolongation of R (p = 0.0001) and TMRTG (p < 0.0001), which returned to baseline values after resuming standard dosage. No differences were observed among patients randomized to 75 mg. Conclusions: T2DM patients with suboptimal clopidogrel response have enhanced platelet procoagulant activity compared to patients with optimal response, which can be down-regulated by more potent platelet P2Y12inhibition using high clopidogrel maintenance dosing. © 2008 Elsevier Ltd. All rights reserved.
Clopidogrel; Diabetes mellitus; Platelets; Thrombosis; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticlopidine; Purinergic P2 Receptor Antagonists; Hematology
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/325286
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 34
social impact